ProLynx Issues U.S. Patent Covering Controlled Drug Release From Dendrimers
April 22, 2014 16:00 ET
|
ProLynx LLC
SAN FRANCISCO, April 22, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs today...
ProLynx Publishes Results of Ultralong Half-Life PEG-SN38 Pro-Drug With Lower Intestinal Toxicity
March 27, 2014 16:00 ET
|
ProLynx LLC
SAN FRANCISCO, March 27, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC today announced a publication in the Journal of Medicinal Chemistry on macromolecular pro-drugs that provide the irinotecan...
ProLynx Issues U.S. Patent Covering Beta-Eliminative Linkers
March 25, 2014 15:24 ET
|
ProLynx LLC
SAN FRANCISCO, March 25, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs –...